Afuco™ Anti-TNF ADCC Therapeutic Antibody (Golimumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TNF alpha. Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug, Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor.
Golimumab is as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Golimumab is as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-062 |
| Pricing | Inquiry |
| Host | Human |
| Target | TNF |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |